Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Jan Maarten Van Der Zwan, Annalisa Trama, Renée Otter, Nerea Larrañaga, Andrea Tavilla, Rafael Marcos-Gragera, Angelo Paolo Dei Tos, Eric Baudin, Graeme Poston, Thera Links

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs). A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%). Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended.

Original languageEnglish
Pages (from-to)2565-2578
Number of pages14
JournalEuropean Journal of Cancer
Volume49
Issue number11
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Neuroendocrine Tumors
Neoplasms
Carcinoma
Survival
Incidence
Population
Registries
Pancreas
Thyroid Gland
Databases

Keywords

  • Cancer registry
  • Incidence
  • Neuroendocrine
  • Prevalence
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Der Zwan, J. M., Trama, A., Otter, R., Larrañaga, N., Tavilla, A., Marcos-Gragera, R., ... Links, T. (2013). Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer, 49(11), 2565-2578. https://doi.org/10.1016/j.ejca.2013.02.029

Rare neuroendocrine tumours : Results of the surveillance of rare cancers in Europe project. / Van Der Zwan, Jan Maarten; Trama, Annalisa; Otter, Renée; Larrañaga, Nerea; Tavilla, Andrea; Marcos-Gragera, Rafael; Dei Tos, Angelo Paolo; Baudin, Eric; Poston, Graeme; Links, Thera.

In: European Journal of Cancer, Vol. 49, No. 11, 07.2013, p. 2565-2578.

Research output: Contribution to journalArticle

Van Der Zwan, JM, Trama, A, Otter, R, Larrañaga, N, Tavilla, A, Marcos-Gragera, R, Dei Tos, AP, Baudin, E, Poston, G & Links, T 2013, 'Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project', European Journal of Cancer, vol. 49, no. 11, pp. 2565-2578. https://doi.org/10.1016/j.ejca.2013.02.029
Van Der Zwan, Jan Maarten ; Trama, Annalisa ; Otter, Renée ; Larrañaga, Nerea ; Tavilla, Andrea ; Marcos-Gragera, Rafael ; Dei Tos, Angelo Paolo ; Baudin, Eric ; Poston, Graeme ; Links, Thera. / Rare neuroendocrine tumours : Results of the surveillance of rare cancers in Europe project. In: European Journal of Cancer. 2013 ; Vol. 49, No. 11. pp. 2565-2578.
@article{9df140b1081b48848e35434f02e1eab3,
title = "Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project",
abstract = "Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs). A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50{\%}; survival was low (12{\%}) for poorly differentiated endocrine carcinoma, and relatively high (64{\%}) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82{\%}). Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended.",
keywords = "Cancer registry, Incidence, Neuroendocrine, Prevalence, Survival",
author = "{Van Der Zwan}, {Jan Maarten} and Annalisa Trama and Ren{\'e}e Otter and Nerea Larra{\~n}aga and Andrea Tavilla and Rafael Marcos-Gragera and {Dei Tos}, {Angelo Paolo} and Eric Baudin and Graeme Poston and Thera Links",
year = "2013",
month = "7",
doi = "10.1016/j.ejca.2013.02.029",
language = "English",
volume = "49",
pages = "2565--2578",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Rare neuroendocrine tumours

T2 - Results of the surveillance of rare cancers in Europe project

AU - Van Der Zwan, Jan Maarten

AU - Trama, Annalisa

AU - Otter, Renée

AU - Larrañaga, Nerea

AU - Tavilla, Andrea

AU - Marcos-Gragera, Rafael

AU - Dei Tos, Angelo Paolo

AU - Baudin, Eric

AU - Poston, Graeme

AU - Links, Thera

PY - 2013/7

Y1 - 2013/7

N2 - Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs). A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%). Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended.

AB - Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs). A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%). Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended.

KW - Cancer registry

KW - Incidence

KW - Neuroendocrine

KW - Prevalence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84879314990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879314990&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.02.029

DO - 10.1016/j.ejca.2013.02.029

M3 - Article

C2 - 23541566

AN - SCOPUS:84879314990

VL - 49

SP - 2565

EP - 2578

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -